Source:http://linkedlifedata.com/resource/pubmed/id/18508314
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0024623,
umls-concept:C0035647,
umls-concept:C0077923,
umls-concept:C0229671,
umls-concept:C0231221,
umls-concept:C0369303,
umls-concept:C0441889,
umls-concept:C0681850,
umls-concept:C1527178,
umls-concept:C1550501,
umls-concept:C1556094,
umls-concept:C1705938,
umls-concept:C1706203,
umls-concept:C2349001,
umls-concept:C2697811
|
pubmed:issue |
4
|
pubmed:dateCreated |
2008-6-23
|
pubmed:abstractText |
A total of 5,209 asymptomatic, middle-aged subjects, whose serum pepsinogen (PG) and Helicobacter pylori antibody levels had been assessed, were followed for 10 years. Subjects with positive serum H. pylori antibodies (>50 U/mL) had an increased cancer risk (HR = 3.48, 95% CI = 1.26-9.64). Risk of gastric cancer increased as the antibody level increased; the H. pylori-positive group with antibody levels >500 U/mL had the highest incidence rate (325/100,000 person-years). Cancer development also increased with a reduced serum PG I level or a reduced PG I/II ratio; the risk was significantly elevated with serum PG I level <or=30 ng/mL (HR = 3.54, 95% CI = 1.95-6.40) or PG I/II ratio <or=3.0 (HR = 4.25, 95% CI = 2.47-7.32). Furthermore, the risk of diffuse-type cancer increased as PG II level increased; it was significantly elevated with PG II level >or=30 ng/mL (HR = 3.81, 95% CI = 1.10-13.21). Using H. pylori antibody and PG levels, subgroups with an especially high or low cancer incidence rate could be identified. H. pylori-negative or indeterminate subjects with low PG level (PG I <or=30 ng/mL or PG I/II ratio <or=2.0) or H. pylori-positive subjects with antibody levels >500 U/mL and a low PG level were among the subgroups with a high cancer incidence rate (over 400/100,000 person-years). In contrast, H. pylori-negative subjects with a PG I level >70 ng/mL or a PG I/II ratio >3.0 had the lowest risk; none of these subjects developed cancer. Thus, serum PG levels and/or H. pylori antibody levels can be used to predict the risk of cancer in individuals with H. pylori-related gastritis from the general population.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1097-0215
|
pubmed:author |
pubmed-author:AriiKenjiK,
pubmed-author:EnomotoShotaroS,
pubmed-author:FujishiroMitsuhiroM,
pubmed-author:IchinoseMasaoM,
pubmed-author:IguchiMikitakaM,
pubmed-author:MagariHirohitoH,
pubmed-author:MoharaOsamuO,
pubmed-author:MukoubayashiChizuC,
pubmed-author:OkaMasashiM,
pubmed-author:TakeshitaTatsuyaT,
pubmed-author:TamaiHideyukiH,
pubmed-author:UtsunomiyaHirotoshiH,
pubmed-author:YamamichiNobutakeN,
pubmed-author:YanaokaKimihikoK,
pubmed-author:YoshimuraNorikoN
|
pubmed:copyrightInfo |
(c) 2008 Wiley-Liss, Inc.
|
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
123
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
917-26
|
pubmed:meshHeading |
pubmed-meshheading:18508314-Adult,
pubmed-meshheading:18508314-Antibodies, Bacterial,
pubmed-meshheading:18508314-Cohort Studies,
pubmed-meshheading:18508314-Helicobacter Infections,
pubmed-meshheading:18508314-Helicobacter pylori,
pubmed-meshheading:18508314-Humans,
pubmed-meshheading:18508314-Japan,
pubmed-meshheading:18508314-Longitudinal Studies,
pubmed-meshheading:18508314-Middle Aged,
pubmed-meshheading:18508314-Pepsinogen A,
pubmed-meshheading:18508314-Risk Factors,
pubmed-meshheading:18508314-Stomach Neoplasms
|
pubmed:year |
2008
|
pubmed:articleTitle |
Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels.
|
pubmed:affiliation |
Second Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama-city, Wakayama 641-0012, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|